A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL

CD19 is ubiquitously expressed on chronic lymphocytic leukemia (CLL) cells and is therefore an attractive candidate for antibody targeting. XmAb5574 (aka MOR00208) is a novel humanized CD19 monoclonal antibody with an engineered Fc region to enhance Fcγ receptor binding affinity. Here we report resu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2014-12, Vol.124 (24), p.3553-3560
Hauptverfasser:	Woyach, Jennifer A., Awan, Farrukh, Flinn, Ian W., Berdeja, Jesus G., Wiley, Elizabeth, Mansoor, Sharmeen, Huang, Ying, Lozanski, Gerard, Foster, Paul A., Byrd, John C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - pharmacokinetics Antibodies, Neoplasm - administration & dosage Antigens, CD19 Antineoplastic Agents - administration & dosage Antineoplastic Agents - pharmacokinetics Clinical Trials and Observations Female Half-Life Humans Immunoglobulin Constant Regions - administration & dosage Leukemia, Lymphocytic, Chronic, B-Cell - blood Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Male Maximum Tolerated Dose Middle Aged Recurrence Time Factors Tomography, X-Ray Computed
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!